It would have been interesting to have sat in on the senior management meetings at Merck that thrashed out the Organon ...

Thank you for joining Organon's first quarter earnings call ... Renflexis and Hadlima are mainly supplied from Korea and the EU. For recently acquired Tofidence, that product is manufactured in China, ...

This news release contains certain forward-looking statements relating to BAT8006, BAT8008, BAT8010, BAT1006, BAT1308 or the product pipelines in general of Bio-Thera Solutions. Readers are ...

In another development, Organon has acquired the U.S. rights to TOFIDENCE™, a biosimilar to ACTEMRA®, from Biogen, further expanding its arthritis treatment portfolio. Furthermore, Biogen plans to ...

At the top of April, Organon announced the acquisition of Tofidence (tocilizumab-bavi), a biosimilar approved by the FDA in October 2023 for the treatment of rheumatoid arthritis, giant cell arteritis ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global ...